nach oben

Clinical Rheumatology

Erschienen in:

01.02.2011 | Review Article

Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review

verfasst von: Priscila Mattos, Mittermayer B. Santiago

Erschienen in: Clinical Rheumatology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Over the last few years, several studies in patients with systemic lupus erythematosus (SLE) have demonstrated an association between valvulopathy, including Libman–Sacks endocarditis (LS) and the presence of antiphospholipid antibodies (aPL), suggesting a role of these antibodies in the pathogenesis of the lesions. On the other hand, other studies found no such association. The aim of the present study is to analyze, by means of a systematic review, the existent evidences about the association between aPL and valvular lesions, including LS endocarditis, in patients with SLE. The information was obtained through searches for articles in the MEDLINE (1966 to 2010), SciELO, and LILACS databases, using the following key words: “Libman–Sacks endocarditis”, “antiphospholipid and Libman–Sacks”, “antiphospholipid and valvular heart disease”, “antiphospholipid and verrucous endocarditis”, “antiphospholipid and heart”, “antiphospholipid and valvular vegetations”, “anticardiolipin antibodies” and the corresponding translations in Portuguese. Twenty articles were found, which evaluated the association between the presence of aPL and valvulopathy. Thirteen of these studies evaluated the association of aPL with the LS lesion. Of the 20 articles, 15 demonstrated a positive association between aPL and valvular lesions, whereas 5 articles demonstrated that there was no association. Evidence of an association between the presence of aPL and valvular lesion was demonstrated in the majority of studies. Nevertheless, the possible role of these antibodies in the etiopathogenesis of the lesion has not yet been proved.

Asherson RA, Hughes GR (1989) The expanding spectrum of Libman Sacks endocarditis: the role of antiphospholipid antibodies. Clin Exp Rheumatol 7(3):225–228PubMed

Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ et al (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335(8705):1544–1547CrossRefPubMed

Hughes GR, Harris NN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13(3):486–489PubMed

Shoenfeld Y (2003) Systemic antiphospholipid syndrome. Lupus 12(7):497–498CrossRefPubMed

Asherson RA, Cervera R (2003) Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol 25(1):61–78CrossRefPubMed

Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum 46(4):1019–1027CrossRefPubMed

Amoroso A, Cacciapaglia F, De CS, Battagliese A, Coppolino G, Galluzzo S et al (2006) The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin Exp Rheumatol 24(3):287–294PubMed

Diaz RA, Athanassopoulos G, Nihoyannopoulos P (1993) Systemic lupus erythematosus: valvular regurgitation and its relation to anticardiolipin antibodies. Rev Med Chil 121(2):156–161PubMed

Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK et al (2006) Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 54(12):3918–3925CrossRefPubMed

10.

Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ et al (1990) Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335(8705):1541–1544CrossRefPubMed

11.

Lolli C, Foscoli M, Giofre R, Tarquinii M, Pasquali S, Toschi GP (1993) Cardiac anomalies in systemic lupus erythematosus: their prevalence and relation to duration, disease activity and the presence of antiphospholipid antibodies. G Ital Cardiol 23(11):1125–1134PubMed

12.

Moyssakis I, Tektonidou MG, Vasilliou VA, Samarkos M, Votteas V, Moutsopoulos HM (2007) Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 120(7):636–642CrossRefPubMed

13.

Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM (1990) Cardiac abnormalities in systemic lupus erythematosus. association with raised anticardiolipin antibodies. Circulation 82(2):369–375PubMed

14.

Perez-Villa F, Font J, Azqueta M, Espinosa G, Pare C, Cervera R et al (2005) Severe valvular regurgitation and antiphospholipid antibodies in systemic lupus erythematosus: a prospective, long-term, followup study. Arthritis Rheum 53(3):460–467CrossRefPubMed

15.

Cervera R, Font J, Pare C, Azqueta M, Perez-Villa F, Lopez-Soto A et al (1992) Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 51(2):156–159CrossRefPubMed

16.

Metz D, Jolly D, Graciet-Richard J, Nazeyrollas P, Chabert JP, Maillier B et al (1994) Prevalence of valvular involvement in systemic lupus erythematosus and association with antiphospholipid syndrome: a matched echocardiographic study. Cardiology 85(2):129–136CrossRefPubMed

17.

Jouhikainen T, Pohjola-Sintonen S, Stephansson E (1994) Lupus anticoagulant and cardiac manifestations in systemic lupus erythematosus. Lupus 3(3):167–172CrossRefPubMed

18.

Leung WH, Wong KL, Lau CP, Wong CK, Liu HW (1990) Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89(4):411–419CrossRefPubMed

19.

Sturfelt G, Eskilsson J, Nived O, Truedsson L, Valind S (1992) Cardiovascular disease in systemic lupus erythematosus. a study of 75 patients form a defined population. Med Baltim 71(4):216–223

20.

Giunta A, Picillo U, Maione S, Migliaresi S, Valentini G, Arnese M et al (1993) Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. Acta Cardiol 48(2):183–197PubMed

21.

Leszczynski P, Straburzynska-Migaj E, Korczowska I, Lacki JK, Mackiewicz S (2003) Cardiac valvular disease in patients with systemic lupus erythematosus. relationship with anticardiolipin antibodies. Clin Rheumatol 22(6):405–408CrossRefPubMed

22.

Gabrielli F, Alcini E, Di Prima MA, Mazzacurati G, Masala C (1995) Cardiac valve involvement in systemic lupus erythematosus and primary antiphospholipid syndrome: lack of correlation with antiphospholipid antibodies. Int J Cardiol 51(2):117–126CrossRefPubMed

23.

Gleason CB, Stoddard MF, Wagner SG, Longaker RA, Pierangeli S, Harris EN (1993) A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J 125(4):1123–1129CrossRefPubMed

24.

Ramonda R, Doria A, Villanova C, Vaccaro E, Punzi L, Fasoli G et al (1992) Evaluation of cardiac involvement in systemic lupus erythematosus. clinical and echographic study. Rev Rhum Mal OsteÂo Artic 59(12):790–796

25.

Roldan CA, Shively BK, Lau CC, Gurule FT, Smith EA, Crawford MH (1992) Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 20(5):1127–1134CrossRefPubMed

26.

Alves LJ, Hydalgo L, Rolim LF, Campagnone GZ, Aidar MT, Novaes GS et al (1997) Clinical and laboratory diagnosis of heart disease in systemic lupus erythematosus. Arq Bras Cardiol 68(2):79–83PubMed

27.

Hojnik M, George J, Ziporen L, Shoenfeld Y (1996) Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93(8):1579–1587PubMed

28.

Lee JL, Naguwa SM, Cheema GS, Gershwin ME (2009) Revisiting Libman–Sacks endocarditis: a historical review and update. Clin Rev Allergy Immunol 36(2–3):126–130CrossRefPubMed

29.

Menard GE (2008) Establishing the diagnosis of Libman–Sacks endocarditis in systemic lupus erythematosus. J Gen Intern Med 23(6):883–886CrossRefPubMed

30.

Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y (2007) Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 6(6):379–386CrossRefPubMed

31.

Asherson RA, Cervera R (1991) Antiphospholipid antibodies and the heart. lessons and pitfalls for the cardiologist. Circulation 84(2):920–923PubMed

32.

Bouma W, Klinkenberg TJ, van der Horst IC, Wijdh-den HI, Erasmus ME, Bijl M et al (2010) Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature. J Cardiothorac Surg 5:13PubMed

33.

Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD (1989) Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 86(4):407–412CrossRefPubMed

34.

Ford SE, Charrette EJ, Knight J, Pym J, Ford P (1990) A possible role for antiphospholipid antibodies in acquired cardiac valve deformity. J Rheumatol 17(11):1499–1503PubMed

35.

Ziporen L, Goldberg I, Arad M, Hojnik M, Ordi-Ros J, Afek A et al (1996) Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5(3):196–205CrossRefPubMed

36.

Crozier IG, Li E, Milne MJ, Nicholls MG (1990) Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol 65(16):1145–1148CrossRefPubMed

37.

Khamashta MA, Gil A, Asherson RA, Vazquez JJ, Hughes GR (1989) Antiphospholipid antibodies, valvular heart disease and systemic lupus erythematosus. Am J Med 86(5):633–634CrossRefPubMed

38.

Seward JB, Khandheria BK, Oh JK, Abel MD, Hughes RW Jr, Edwards WD et al (1988) Transesophageal echocardiography: technique, anatomic correlations, implementation, and clinical applications. Mayo Clin Proc 63(7):649–680PubMed

39.

Shively BK, Gurule FT, Roldan CA, Leggett JH, Schiller NB (1991) Diagnostic value of transesophageal compared with transthoracic echocardiography in infective endocarditis. J Am Coll Cardiol 18(2):391–397CrossRefPubMed

40.

Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y (2006) Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatol Oxf Suppl 4:iv8–iv13CrossRef

41.

Bulkley BH, Roberts WC (1975) The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. a study of 36 necropsy patients. Am J Med 58(2):243–264CrossRefPubMed

42.

Galve E, Candell-Riera J, Pigrau C, Permanyer-Miralda G, Garcia-Del-Castillo H, Soler-Soler J (1988) Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 319(13):817–823CrossRefPubMed

Titel: Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review
verfasst von: Priscila Mattos
Mittermayer B. Santiago
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 2/2011
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-010-1662-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Osteopathy for musculoskeletal pain patients: a systematic review of randomized controlled trials

Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon

Infrapatellar bursitis in children with juvenile idiopathic arthritis: a case series

Adaptation of Turkish version of the questionnaire Quick Disability of the Arm, Shoulder, and Hand (Quick DASH) in patients with carpal tunnel syndrome

A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma